EVA MARÍA
CIRUELOS GIL
Profesora asociada de Ciencias de la Salud
Complejo Hospitalario de Toledo
Toledo, EspañaPublicaciones en colaboración con investigadores/as de Complejo Hospitalario de Toledo (5)
2021
2020
-
Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)
European Journal of Cancer Care, Vol. 29, Núm. 4
-
Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)
Breast Cancer Research and Treatment, Vol. 184, Núm. 2, pp. 469-479
2019
-
Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study
Breast Journal, Vol. 25, Núm. 2, pp. 219-225
2016
-
Single arm, multicentre, non-randomized open-label trial to evaluate the safety of eribulin in third line chemotherapy in patients with HER2-negative metastatic or locally advanced breast cancer previously treated with anthracyclines and taxanes: Onsite study (ONCOSUR 2012-02)
Annals of Oncology, Vol. 27, pp. vi76